CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success

CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success

Chimeric antigen receptor (CAR)-engineered T cells represent a breakthrough in personalized medicine. In this strategy, a patient's own T lymphocytes are genetically reprogrammed to encode a synthetic receptor that binds a tumor antigen, allowing T cells to recognize and kill antigen-expressing...

Full description

Bibliographic Details
Main Authors: Kristen B. Long, Regina M. Young, Alina C. Boesteanu, Megan M. Davis, J. Joseph Melenhorst, Simon F. Lacey, David A. DeGaramo, Bruce L. Levine, Joseph A. Fraietta
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-12-01
Series:Frontiers in Immunology
Subjects:
CAR T cell
immunotherapy
cancer
solid tumor
microenvironment
adoptive cell therapy
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.02740/full

Similar Items

Similar Items